Slide 1: A proven technology, new opportunities
For personal use only A proven technology, new opportunities Investor Briefing September 2013
Slide 2: Alzheimer's disease is among the most significant crises of the 21st century
For personal use only Alzheimer’s disease is among the most significant social, health and economic crises of the 21st century.
Slide 3: Focus on early detection
Focus on early detection For personal use only – 682 million people living with dementia in 2055. Incidence of dementia is increasing worldwide. – Early detection. Research for possible treatments mostly focused on earlier stages of the disease, making early detection important. – 20-30 years. Numbe
Slide 4: A shift in public policy
A shift in public policy For personal use only – In Australia, the Coalition announced $200m funding for AD research. – In April 2013, the Obama administration announced the Brain Initiative, a collaborative research program projected to cost over $300m per year for 10 years. – In the USA, the Annua
Slide 5: Cogstate is uniquely placed
Cogstate is uniquely placed For personal use only – Culturally neutral, free of language, non-verbal, easy to use, computerised cognitive test that can be distributed via the internet. – Widely accepted and validated commercially and academically. – A leading research tool for the early detection of
Slide 6: This is our purpose
This is our purpose For personal use only Cogstate was founded, in 1999, with the idea that the technology could be used in the detection of the first signs of dementia.
Slide 7: Over years of dementia research
Over 10 years of dementia research For personal use only – Experience: Cogstate included in clinical drug trials and research studies for over 10 years. – Reputation: Cogstate has developed a reputation for exceptional science and reliable technology. – Compliance: Our involvement in pharmaceutical
Slide 8: Leading the field
Leading the field For personal use only • Cogstate provides: – GPs with the tools for accurate and easy measurement of cognitive function at the point of care leading to better health outcomes for the patient. COGNIGRAM™ is the first product to achieve this goal. – Cutting edge tools to assess, moni
Slide 9: We already assist decision making
We already assist decision making For personal use only – In sports concussion, we have worked extensively for 10 years in the general community. – We have learned how to communicate our results in a clear and concise manner. – We have enabled decision making: • AFL / NRL / NBA / NHL doctors all use
Slide 10: Accepted & used in critical studies
Accepted & used in critical studies For personal use only Critical prospective studies have all selected Cogstate for inclusion: – AIBL (Australian Imaging Biomarkers & Lifestyle); – Anti-Amyloid Treatment in Asymptomatic AD (A4); – Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU); – B
Slide 11: A new phase in the evolution
A new phase in the evolution For personal use only – FY13 eighth consecutive year of growth, driven by clinical trials. – Following restructure along four business lines (Cognigram, Clinical Trials, Axon, R&D) significant investment into new commercial opportunities underway. – New revenue streams i
Slide 12: FY13 financial results - overall
FY13 financial results - overall For personal use only – Revenue $12.46m, up 4%. – Net Loss $2.12m.
Slide 13: FY13 financial results – clinical trials
FY13 financial results – clinical trials For personal use only – Revenue of $11.6m. – At 1 July 2013, $8.61m of contracted revenue to be recognised in future periods, compared to $7.84m in the year prior. – Organic growth being driven by larger, later stage contracts and entry into new disease areas
Slide 14: FY13 financial results - healthcare
FY13 financial results - healthcare For personal use only – COGNIGRAM test launched in Canada to GPs. – Over 450 physicians registered. – Rollout of testing centres to be completed by end of 2013. – Focused on commercialisation in new markets, increasing reimbursement, and expanding to other tests (
Slide 15: FY13 financial results - sports
FY13 financial results - sports For personal use only – $0.6m revenue, of which $0.4m is new revenue from cognitive training products. – 6 elite American teams signed in FY13, and 4 human performance labs (elite training centres) using the technology. – Transferable technology in to new markets and
Slide 16: FY14 business outlook
FY14 business outlook For personal use only Capitalise on our leadership position to: – Sustain organic growth in clinical trials business, with focus on new indications. – Establish COGNIGRAM in new geographic markets, extract revenue growth in Canada. Invest in the commercialisation and market rol
Slide 17: For personal use only
For personal use only COGSTA’lhe ASSESS + MONITOR « IMPROVE